3TR First progress meeting: One year completed, six years ahead
On 02-03 October 2020, the 3TR consortium gathered virtually for its first progress meeting. More than 220 participants came together to discuss the progress of the project one year after its kick-off. Even though the consortium was not able to meet in person due to the COVID-19 pandemic, the meeting was still a great opportunity for the 69 academic and industrial partners to provide more detailed feedback on this flagship project.
The Project Coordinator, Marta Alarcón Riquelme (FPS), and the Project Leader, Terry Means (Sanofi), were setting the stage on the first meeting day and had the privilege to welcome the scientific, ethics and patient advisors as well as the project’s scientific officer of IMI, Isabella Tamagnini. The rest of the day was filled with presentations from work package leaders and co-leaders as well as from different disease focused working groups who gave an update on their work, presented achievements and addressed challenges as well as upcoming activities. The second meeting day focused more on trans-disease activities: Next to the scientific activities, the engagement of regulatory bodies including aspects like patient reported outcomes were discussed.
At the end of the meeting, Marta Alarcón Riquelme (FPS) concluded: “We can look back to a very successful project start and an exciting first year showing a strong collaboration. Of course, the COVID-19 pandemic represented a huge challenge for many partners in the last months. Nevertheless, we are now well underway to achieve our goal to identify molecular signatures for non-response to treatments and therefore increase the knowledge of the molecular pathways and mechanisms within and across these immune mediated diseases. We have to keep up the excellent work to the benefit of our most important stakeholders – the patients. I am looking forward to six more exciting years in the 3TR project.” And Terry Means (Sanofi) stated that “it is great to see the progress our project has made within the first year; 3TR has now a strong collaborative foundation, for example the design of the different clinical studies is close to being finalised. The discussions, though just virtual, were valuable and helped to identify new points of action to reach our project goal.”
For more information on upcoming project outputs, follow us also on twitter @3TR_IMI.